U.S. FDA Grants Priority Review For Daklinza (daclatasvir) sNDAs
Go back to U.S. FDA Grants Priority Review For Daklinza (daclatasvir) sNDAs| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 67.01 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $67.01 | 52 Week High | $77.12 | |||
| Open | $67.01 | 52 Week Low | $49.03 | |||
| Day High | $67.01 | P/E | 43.51 | |||
| Day Low | $67.01 | EPS | $1.54 | |||
| Volume | 689 | |||||
